WIN Consortium Appoints Professor Waun Ki Hong as Special Advisor to Oversee Its Combined Targeted Triple-Therapy Strategy Aiming to Achieve Significant Impact on Survival in Metastatic Lung Cancer
Worldwide Innovative Networking - WIN Consortium announces today the appointment of Professor Waun Ki Hong from the University of Texas MD Anderson Cancer Center, as Special Advisor and member of the Executive Committee. Professor Waun Ki Hong will oversee the new strategy of WIN consortium and the next generation of clinical trials aiming to significantly impact the overall survival of lung cancer patients. These programs will be disclosed at the WIN 2015 symposium, to be held on June 29-30 in Paris, France.
Prof. Waun Ki Hong (Photo: Business Wire)
The goal of WIN is to bring precision cancer medicine to patients, world wide, as rapidly and effectively as possible. We are focusing on lung cancer because of its major importance as a cause of death, and because progress in prolonging some patient’s lives has been made with therapies targeting aberrant genes in this form of cancer over the past few years. The pillars of the WIN strategy will be the triple targeted therapy combinations clinical trials in metastatic lung cancer patients and the discovery and validation of non-invasive biomarkers for the diagnosis of lung cancer in stage I to enable earlier diagnosis for an increased number of patients.
“WIN Consortium proudly announces that Professor Waun Ki Hong, who pioneered personalized cancer therapy with BATTLE trials in lung cancer will oversee and coordinate the strategy of combinations of targeted therapies and next generation of clinical trials of WIN Consortium in his role of Special Advisor and lung expert.” said Dr. John Mendelsohn, Chairman of WIN. “During the WIN symposium 2015 the results and the learnings from WINTHER, the first trial of WIN Consortium, will be presented. It will also be the occasion to disclose the concept underlying the WIN Consortium global and exhaustive approach towards Non Small Cell Lung Cancer and present the design of the trials based on a new scientific rationale aiming to significantly impact survival of lung cancer patients.’’ added Dr. John Mendelsohn.
“I am thrilled to contribute to this unique and unprecedented innovative approach initiated by this wonderful assembly of cancer stakeholders gathered in WIN consortium. The novel approach proposed to be tested by WIN has been recently published in Oncotarget . It consists in a new modelling of the lung disease with a pragmatic matching process of the biology of each patient to the best combination of triple targeted therapies. It brings to the concept of Precision Cancer Medicine an unprecedented dimension.’’ said Professor Waun Ki Hong.
“Following the historical success of the triple-therapy approach in AIDS and tuberculosis, it has become urgent to test this hypothesis in lung cancer. Lung cancer remains today one of the most devastating of cancers. The current therapeutic approach with targeted monotherapies produce high regression rates, albeit for limited patient subgroups, who inevitably succumb. Customized combinations that incorporate breakthroughs in immunotherapy and matched targeted therapies are the next step” says Razelle Kurzrock, Head of Clinical Trials Committee of the WIN Consortium and global Principal Investigator of the future combination trial of the WIN Consortium.
“Join the greatest experts invited to debate and reshape the future of oncology. We count on your attendance and active participation in this unprecedented forum of discussion and round tables.“, said Alexander Eggermont, Vice Chair of the WIN Consortium.
Catherine Bresson, Director of operations of WIN added: “All stakeholders of cancer care are expected. We encourage patients’ associations and cancer research associations as well as philanthropists to join us in the battle against lung cancer. Their involvement and contribution are essential to help WIN bringing progress more quickly to patients”.
About Waun Ki Hong:
Waun Ki Hong, MD, FACP, DMSc (Hon) is an American Cancer Society Professor, the Samsung Distinguished University Chair in Cancer Medicine emeritus, and Professor of Cancer Medicine at The University of Texas MD Anderson Cancer Center, where he served as Chairman of the Department of Thoracic/Head & Neck Medical Oncology from 1993-2005 and as Head of the Division of Cancer Medicine from 2001-2014. Dr. Hong is a leading authority on head/neck and lung cancers. His specialty is medical oncology with expertise in the areas of molecular therapeutics, cancer prevention, clinical investigation, and personalized targeted therapy.
Dr. Hong is the recipient of numerous distinguished national and international awards including, election to the Institute of Medicine (IOM) of the National Academies and election as an Inaugural Fellow of the AACR Academy. He is also a recipient of The American Cancer Society Medal of Honor for Clinical Research; the AACR Joseph A. Burchenal and Rosenthal Foundation Awards; the ASCO David Karnofsky Award; and the Ho-Am Prize in Medicine from South Korea.
A national and international leader in medical oncology, Dr. Hong has trained clinical oncologists throughout the world and participated in creating national cancer policy through the National Cancer Advisory Board (NCAB), the US FDA Oncologic Drug Advisory Committee, the NCI Board of Scientific Advisors, the American Society of Clinical Oncology Board of Directors, and as past president of the American Association for Cancer Research.
Dr. Hong has served on the editorial boards of 17 scientific journals. He has authored more than 689 scientific papers and edited 11 books, including the 7th and 8th editions of Holland-Frei Cancer Medicine.
About WIN 2015 Symposium:
Novel Targets, Innovative Agents, Advanced technologies: A WINning strategy!
June 29-30, 2015 Paris: Here are the five top reasons to attend this exceptional scientific event:
- Contribute building the WINning strategies for personalized cancer care
- Hear the latest about groundbreaking technologies big trials and “big data”
- Learn about WIN Consortium, its strategy and its global clinical trials
- Meet global leaders: network with top executives from the academic, pharma/biotech and regulatory environment
- Discuss your own data with an international audience of peers and receive CME credits
With renowned participation of: James Allison, Andrea Califano, James Doroshow, Alexander Eggermont, Waun Ki Hong, Razelle Kurzrock, John Mendelsohn, Richard L. Schilsky, Ton Schumacher, Jean-Charles Soria, Ralph Weichselbaum, Antoine Yver and many others.
About WIN Consortium:
WIN Consortium was founded on the premise that we can accomplish more together than what any one organization can accomplish alone: to significantly improve cancer patients’ survival and quality of life. WIN members include organizations representing all stakeholders in personalized cancer medicine: cancer centers in 16 countries and 4 continents, major technology and pharmaceutical industries, cancer charities and health payer.
Industries
Agilent Technologies | Ariana Pharma| AstraZeneca| Blue Cross Blue Shield Association | Foundation Medicine| GE Healthcare| Oracle | Pfizer | Takeda
Non-Profits
ARC Foundation| Cancer Research UK | CEO Roundtable on Cancer | EORTC | Sage Bionetworks
Academics
ASAN Medical Center, Korea | Ben-Gurion University of the Negev, Israel | Cambridge Cancer Centre, UK | Chaim Sheba Medical Center, Israel | DKFZ/NCT, Germany | Fudan University, China | Gustave Roussy, France | Hadassah University, Israel | Hospital Cancer de Barretos, Brazil | INCLIVA, Spain | IOCN & UMF, Romania | Istituto Nazionale dei Tumori, Italy | King Hussein Cancer Center, Jordan | Memorial Sloan Kettering, USA | McGill Segal Cancer Center, Canada | National Cancer Centre Singapore | NYU, USA | Princess Margaret Hospital, Canada | TATA Memorial Hospital, India | UC San Diego, USA | UT MDAnderson, USA | Vall d’Hebron, Spain | Yonsei Cancer Center, Korea
Join our WIN Linkedin group today to be informed about the WIN 2015 Symposium, discover like-minded professionals and join discussions https://www.linkedin.com/company/win-symposium or follow us on twitter @ WIN_Consortium
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20150414005036/en/
Contact information
WIN Consortium
Catherine Bresson, Tel: + 33 1 42 11 40 20
Director
of WIN Consortium operations
catherine.bresson@winconsortium.org
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo